Anzeige
Meldung des Tages: Gold im Fokus: Warum diese milliardenschwere Goldaktie vom aktuellen Goldumfeld profitieren könnte

VistaGen Therapeutics Aktie News

Aktie
WKN:  A3EHA1 ISIN:  US92840H4002 US-Symbol:  VTGN Branche:  Biotechnologie Land:  USA
0,5262 $
-0,0174 $
-3,20%
0,44637 € 04.02.26
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

VistaGen Therapeutics News

05:19 Uhr - PR Newswire
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN PR Newswire
04:34 Uhr - PR Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
04.02.26 - PR Newswire
VTGN CLASS ACTION ALERT: Robbins LLP Urges Vistagen Therapeutics, Inc. Stockholders to Reach Out for Information About the Securities Class Action Lawsuit
VTGN CLASS ACTION ALERT: Robbins LLP Urges Vistagen Therapeutics, Inc. Stockholders to Reach Out for Information About the Securities Class Action Lawsuit PR Newswire
04.02.26 - PR Newswire
March 16, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTGN
March 16, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTGN PR Newswire
04.02.26 - PR Newswire
VTGN INVESTOR ALERT -- LEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS
VTGN INVESTOR ALERT -- LEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS PR Newswire
02.02.26 - PR Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
02.02.26 - PR Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
02.02.26 - PR Newswire
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN PR Newswire
29.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTGN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ...
29.01.26 - PR Newswire
Investors in Vistagen Therapeutics, Inc. Should Contact The Gross Law Firm Before March 16, 2026 to Discuss Your Rights - VTGN
Investors in Vistagen Therapeutics, Inc. Should Contact The Gross Law Firm Before March 16, 2026 to Discuss Your Rights - VTGN PR Newswire
29.01.26 - PR Newswire
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics PR Newswire
29.01.26 - PR Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
29.01.26 - PR Newswire
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN PR Newswire
28.01.26 - PR Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
28.01.26 - PR Newswire
LEVI & KORSINSKY, LLP NOTIFIES INVESTORS OF CLASS ACTION LAWSUIT AGAINST VISTAGEN THERAPEUTICS ALLEGING SECURITIES FRAUD IN DRUG DEVELOPMENT DISCLOSURES
LEVI & KORSINSKY, LLP NOTIFIES INVESTORS OF CLASS ACTION LAWSUIT AGAINST VISTAGEN THERAPEUTICS ALLEGING SECURITIES FRAUD IN DRUG DEVELOPMENT ...
22.01.26 - PR Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
22.01.26 - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics PR Newswire
22.01.26 - PR Newswire
Vistagen Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Vistagen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 - VTGN
Vistagen Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Vistagen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026 - ...
21.01.26 - PR Newswire
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join - Contact Levi & Korsinsky
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join - Contact Levi & Korsinsky PR Newswire
19.01.26 - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +5,17%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »